Back to Agenda
Externally Controlled Trials in Clinical Development: Challenges and Mitigation Strategies
Session Chair(s)
Xiang Zhang, PHD
Head of Medical Affairs and HTA Statistics/Co-lead FORExcellence
CSL Behring, United States
Externally controlled clinical trials emerges as a viable alternative to traditional RCTs but come with risks such as confounding and bias. This session will focus on discussing these challenges and how to mitigate them via design and analysis.
Learning Objective : Identify and describe various sources of bias in externally controlled clinical trials, and illustrate their impact on causal effect estimation; Explain statistical methods developed to estimate causal treatment effect from externally controlled trials; Discuss regulatory perspectives on the use of external controls for drug development and registration.
Speaker(s)
Uncovering the Challenges of Utilizing RWE in Regulatory Decision Making: Barriers, Mitigations and Future Directions
Ran Duan, PHD
Vertex Pharmaceuticals, United States
Director Biometrics
Externally Controlled Trials in Oncology: Regulatory Considerations and a Case Example
Arup Sinha, PHD
FDA, United States
Statistician, OTS, CDER
An EU Regulatory Perspective on External Controls
Andrew Thomson, PHD, MA, MS
European Medicines Agency, Netherlands
Statistician, Methodology Taskforce
Panelist
Charles Lee, MBA, MS
AstraZeneca, United States
Executive Regulatory Science Director
Have an account?